Periprocedural type IVa myocardial infarction and the importance of platelet inhibition

Heart

Volumn 99, Issue 17, 2013, Pages 1225-1226

  Shah, Anoop S V ^a   Mills, Nicholas L ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CREATINE KINASE MB; PLACEBO; TROPONIN;

CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; HEART INFARCTION; HEART INFARCTION TYPE 4; HEART MUSCLE REVASCULARIZATION; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION INHIBITION;

CORONARY ARTERY DISEASE;

ACUTE CORONARY SYNDROME; ADENOSINE MONOPHOSPHATE; CREATINE KINASE, MB FORM; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TROPONIN;

EID: 84881475573     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-303733     Document Type: Editorial

References (11)

1. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv 2010;3:602-10.
2. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005;112:906-15.
3. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67.
4. Leonardi S, Truffa MAM, Neely LM, et al. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart 2013;99:1282-87.
5. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41.
6. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124: e574-651.
7. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011;305:1210-16.
8. Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ 2012;344:e1533.
9. Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002;105:554-6. (Pubitemid 34123427)
10. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51. (Pubitemid 28153440)
11. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inihibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368: 1303-13.